The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

References

• Kebebew E, Clark OH. Medullary thyroid cancer. Curr Treat Options Oncol. 2000;1:359–367.
   PubMedGoogle Scholar
• Verdy M, Weber AM, Roy CC, et al. Hirschsprung’s disease in a family with multiple endocrine neoplasia type 2. J Pediatric Gastroenterol Nutr. 1982;1:603–607.
   PubMed Web of Science ®Google Scholar
• Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989;111:802–806.
   PubMed Web of Science ®Google Scholar
• Drosten M, Pützer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol. 2006;3:564–574.
   PubMedGoogle Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep. 2012;14:97–104.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(Suppl 2):S37–S43.
   PubMed Web of Science ®Google Scholar
• de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27:535–560.
   PubMed Web of Science ®Google Scholar
• Sapio MR, Guerra A, Marotta V, et al. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab. 2011;96:E916–E919.
   PubMed Web of Science ®Google Scholar
• Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9:509–516.
   PubMed Web of Science ®Google Scholar
• Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17:7–16.
   PubMed Web of Science ®Google Scholar
• Moura MM, Cavaco BM, Pinto AE, et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:E863–E868.
   PubMed Web of Science ®Google Scholar
• Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20:863–871.
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–231.
   PubMed Web of Science ®Google Scholar
• Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–641.
   PubMed Web of Science ®Google Scholar
• Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011;29:4837–4838.
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9:314–326.
   PubMed Web of Science ®Google Scholar
• Papotti M, Olivero M, Volante M, et al. Expression of Hepatocyte Growth Factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000;11:19–30.
   PubMed Web of Science ®Google Scholar
• Giunti S, Antonelli A, Amorosi A, et al. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol. 2013;2013:803171.
   PubMed Web of Science ®Google Scholar
• Croyle M, Akeno N, Knauf JA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008;68:4183–4191.
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16:441–467.
   PubMed Web of Science ®Google Scholar
• Kasaian K, Wiseman SM, Walker BA, et al. Putative BRAF activating fusion in a medullary thyroid cancer. Cold Spring Harb Mol Case Stud. 2016;2:a000729.
   Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–2142.
   PubMed Web of Science ®Google Scholar
• Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89:163–168.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr., Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998;58:5523–5528.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Santoro M. Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab. 2014;99:1543–1555.
   PubMed Web of Science ®Google Scholar
• Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics. 2014;8:281–291.
   PubMedGoogle Scholar
• Fallahi P, Ferrari SM, Santini F, et al. Sorafenib and thyroid cancer. BioDrugs. 2013;27:615–628.
   PubMed Web of Science ®Google Scholar
• NCI Drug Dictionary. National Cancer Institute. 2011. Available from: http://cme.nci.nih.gov/drugdictionary/?CdrID=269177
   Google Scholar
• Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14:378–390.
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Med Chem. 2002;45:1300–1312.
   Web of Science ®Google Scholar
• El-Azab AS, Al-Omar MA, Abdel-Aziz AA, et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem. 2010;45:4188–4198.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–7290.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23:6056–6063.
   PubMed Web of Science ®Google Scholar
• Johanson V, Ahlman H, Bernhardt P, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer. 2007;14:433–444.
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34:221–237.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767–772.
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664–2671.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–141.
   PubMed Web of Science ®Google Scholar
• Chougnet CN, Borget I, Leboulleux S, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid. 2015;25:386–391.
   PubMed Web of Science ®Google Scholar
• Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013;19:4239–4248.
   PubMed Web of Science ®Google Scholar
• Erica Jefferson (Media Inquiries). FDA approves new treatment for rare form of thyroid cancer. Silver Spring (MD): Food and Drug Administration; [cited 2011 Apr 7]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.ht
   Google Scholar
• Stephanie Yao (Media Inquiries). FDA approves cometriq to treat rare type of thyroid cancer. Silver Spring (MD): Food and Drug Administration; [cited 2012 Nov 29]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm
   Google Scholar
• FDA approved drugs cabozantinib (CABOMETYX). Silver Spring (MD): Food and Drug Administration; [cited 2016 Apr]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm
   Google Scholar
• Vandetanib shows clinical benefit when combined with docetaxel for lung cancer. ScienceDaily. Accessed [2009 Jun 3]. Available from: https://www.sciencedaily.com/releases/2009/06/090601092237.htm
   Google Scholar
• PrECOG, LLC. Study of vandetanib combined with chemotherapy to treat advanced non-small cell lung cancer [Clinicaltrials.gov identifier: NCT00687297]. Accessed [2012 Nov 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT00687297
   Google Scholar
• Cooper MR, Yi SY, Alghamdi W, et al. Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother. 2014;48:387–394.
   PubMed Web of Science ®Google Scholar
• Massicotte MH, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170:575–582.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. To compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer [ClinicalTrials.gov identifier: NCT01496313]. Accessed [2016 May 5]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01496313
   Google Scholar
• Narayanan VK, Ronghe M, MacGregor FB, et al. Use of vandetanib in metastatic medullary carcinoma of thyroid in a pediatric patient with multiple endocrine Neoplasia 2B. J Pediatr Hematol Oncol. 2016;38:155–157.
   PubMed Web of Science ®Google Scholar
• Baudry C, Paepegaey AC, Groussin L. Reversal of cushing’s syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013;369:584–586.
   PubMed Web of Science ®Google Scholar
• Nella AA, Lodish MB, Fox E, et al. Vandetanib successfully controls medullary thyroid cancer-related cushing syndrome in an adolescent patient. J Clin Endocrinol Metab. 2014;99:3055–3059.
   PubMed Web of Science ®Google Scholar
• Pitoia F, Bueno F, Schmidt A, et al. Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic cushing syndrome. Arch Endocrinol Metab. 2015;59:343–346.
   PubMed Web of Science ®Google Scholar
• Werner RA, Schmid JS, Muegge DO, et al. Prognostic value of serum tumor markers in medullary thyroid cancer patients undergoing vandetanib treatment. Medicine (Baltimore). 2015;94:e2016.
   PubMed Web of Science ®Google Scholar
• Lassalle S, Zangari J, Popa A, et al. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget. 2016;7:30461–30468.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897–905.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Evaluation of efficacy, safety of vandetanib in patients with differentiated thyroid cancer (VERIFY) [ClinicalTrials.gov identifier: NCT01876784]. Accessed [2016 Mar 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01876784
   Google Scholar
• Caprelsa (vandetanib) tablets: US prescribing information. US Food and Drug Administration Center for Drug Evaluation and Research. 2014 [cited 2015 Feb 27]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm327503/022405s007lbl.pdf
   Google Scholar
• Caprelsa (vandetanib): summary of product characteristics. European Medicines Agency; [cited 2015 Feb 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002315/WC500123555.pdf
   Google Scholar
• Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer. 2012;20:909–921.
   PubMed Web of Science ®Google Scholar
• Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1125–1133.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Patel AB, Curry JL, et al. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol. 2015;15:2.
   PubMedGoogle Scholar
• Yoon J, Oh CW, Kim CY. Stevens–Johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23(Suppl 3):S343–S345.
   PubMed Web of Science ®Google Scholar
• Belum VR, Washington C, Pratilas CA, et al. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatr Blood Cancer. 2015;62:798–806.
   PubMed Web of Science ®Google Scholar
• Yang X, Pan X, Cheng X, et al. Risk of gastrointestinal events during vandetanib therapy in patients with cancer: a systematic review and meta-analysis of clinical trials. Am J Ther. 2015. Epub ahead of print.
   Google Scholar
• Hafermann MJ, Namdar R, Seibold GE, et al. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53–58.
   PubMedGoogle Scholar
• Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004;15:330–337.
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Siqueira DR, et al. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol. 2013;168:K51–K54.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295–316.
   PubMed Web of Science ®Google Scholar
• Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol. 2013;75:919–930.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf. 2014;13:723–733.
   PubMed Web of Science ®Google Scholar
• Lodish M, Gkourogianni A, Bornstein E, et al. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. Int J Pediatr Endocrinol. 2015;2015:3.
   PubMed Web of Science ®Google Scholar
• Gild ML, Bullock M, Robinson BG, et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol. 2011;7:617–624.
   PubMed Web of Science ®Google Scholar
• Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013;19:524–529.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Martinelli E, Troiani T, et al. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One. 2011;6:e28841.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf). 2009;70:946–953.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol. 2008;159:283–291.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf). 2008;69:148–152.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, La Motta C, et al. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Surgery. 2014;156:1167–1176.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014;393:56–64.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014;99:E572–E581.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Di Bari F, Ferrari SM, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459–3470.
   PubMed Web of Science ®Google Scholar
• Cascone T, Morelli MP, Morgillo F, et al. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol. 2008;216:698–707.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). A targeted phase I/II trial of ZD6474 (vandetanib; ZACTIMA) plus the proteasome inhibitor, bortezomib (velcade), in adults with solid tumors with a focus on hereditary or sporadic, locally advanced or metastatic medullary thyroid cancer (MTC) [ClinicalTrials.gov identifier: NCT00923247]. Accessed [2016 Aug 31]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00923247.
   Google Scholar
• Troiani T, Lockerbie O, Morrow M, et al. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther. 2006;5:1883–1894.
   PubMed Web of Science ®Google Scholar
• Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res. 2007;13:6450–6458.
   PubMed Web of Science ®Google Scholar
• Wachsberger P, Burd R, Ryan A, et al. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys. 2009;75:854–861.
   PubMed Web of Science ®Google Scholar